Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (SNOA) delivers innovative healthcare solutions through its patented Microcyn® technology, specializing in stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and animal health. This page provides a centralized resource for tracking the company’s latest developments, regulatory milestones, and strategic initiatives.
Access timely updates on FDA clearances, clinical study results, and product launches that demonstrate SNOA’s commitment to non-toxic, evidence-based therapies. Investors and healthcare professionals will find verified information about:
• New product approvals across global markets
• Partnership announcements with medical distributors
• Financial performance and growth strategies
• Research breakthroughs in HOCl applications
All content is curated to meet strict accuracy standards, with direct links to official press releases and validated third-party analyses. Bookmark this page for efficient monitoring of SNOA’s progress in advancing biocompatible wound care and antimicrobial solutions.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has announced the successful registration of its hypochlorous acid-based acne products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA). The company will launch its products through a major UK pharmacy chain, reaching over 1,200 stores nationwide.
The product line features an acne toner and balancing serum, which will be marketed under the retailer's private label brand. These products are based on Sonoma's patented Microcyn technology, utilizing stabilized hypochlorous acid (HOCl). The formulation offers a natural alternative to traditional acne treatments containing alcohol and benzoyl peroxide.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has achieved significant regulatory milestones in the United Kingdom, securing MHRA registration for its manufacturing facility and five key products. The approved products include their Microcyn technology-based hypochlorous acid (HOCl) solutions for wound irrigation, scar management, wound hydrogel, and skin exfoliant.
The company, which develops patented Microcyn® technology-based stabilized HOCl products for various applications including wound care, eye, oral, nasal care, dermatological conditions, podiatry, and animal health care, views the UK market as a significant opportunity for expansion, particularly in wound care and dermatology segments.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company, which develops Microcyn® technology based stabilized hypochlorous acid (HOCl) products, will showcase its prescription and OTC dermatology products at booth 1054.
The AAD annual meeting is a major dermatology conference featuring over 350 exhibitors, nearly 20,000 attendees including 10,000+ medical personnel, and more than 300 educational sessions. Sonoma aims to expand its distributor network and present its portfolio of products for skin care, scar management, and atopic dermatitis.
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q3 fiscal 2025 results with revenues increasing 14% to $3.6 million compared to the prior year. The company achieved positive cash flow from operations, maintaining $5.2 million cash at December 31, 2024.
Key developments include new partnerships with Medline Industries and WellSpring Pharmaceutical to expand U.S. sales, FDA 510(k) clearance for Microcyn technology-based hydrogel, and successful transition to EU Medical Device Regulation for four products. The company relaunched direct sales of prescription dermatology and eye care product lines.
Despite revenue growth, gross margins decreased to 36% from 47% year-over-year due to manufacturing resources allocation for European regulatory requirements. Operating expenses remained flat at $2.3 million, with a quarterly net loss of $0.9 million and EBITDA loss of $1.0 million.
Sonoma Pharmaceuticals (Nasdaq:SNOA) has successfully transitioned four of its products to meet the new European Union Medical Device Regulation (MDR) requirements, achieving Class IIb medical device classification. The products include Microdacyn60® Wound Care, Microdacyn60 Hydrogel, Epicyn® (scar gel), and Pediacyn® for atopic dermatitis.
The EU MDR, adopted in 2017 to replace the Medical Device Directive, requires compliance by December 31, 2028 for non-implantable Class IIb and lower risk devices. The classification was granted after the products met safety and performance requirements and passed conformity assessment, demonstrating their compliance with the new, more stringent European standards.
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the relaunch of its prescription dermatology and eye care product lines in the United States. The company will now directly sell its Microcyn technology-based products, which were previously distributed through a third party. The product lineup includes prescription-strength items like Acuicyn, Epicyn, Levicyn, and Celacyn, along with over-the-counter options Lasercyn Dermal Spray and Gel. These hypochlorous acid-based products will be available from December 9, 2024, with pre-ordering options available.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has received a new FDA 510(k) clearance for its Microcyn technology-based hydrogel. The clearance includes improved biocompatibility and extended shelf life of 24 months for 50mL bottles. The product can be used professionally for managing wounds, dermal irritation, first and second degree burns, and diabetic ulcers. It's also approved for over-the-counter use on minor skin irritations, lacerations, abrasions, and minor burns, including sunburn management.
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q2 FY2025 results with significant improvements across key metrics. Revenue increased 31% to $3.6 million, driven by growth in US (14%), Europe (25%), and Latin America (79%). The company reduced its net loss by 59% to $0.6 million, while achieving positive cash flows from operations of $0.35 million. Gross profit margin improved to 38% from 36% year-over-year. The company strengthened its market position through new distribution agreements for wound care products in the US and Canada, and received FDA clearance for expanded eye care and dermatological product indications.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in MEDICA 2024, the world's largest medical trade fair, taking place in Düsseldorf, Germany from November 11-14, 2024. The event is expected to attract over 120,000 visitors from 70+ countries and 5,300+ exhibitors. Sonoma will showcase its Microcyn technology-based products for wound care, eye care, dermatological conditions, and other applications at booth F12-5 in Hall 15. The company aims to expand its distributor network and forge new partnerships through this global platform.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has expanded its partnership with a leading global healthcare distributor for marketing and distributing its wound care products in Canada. This amendment to their existing agreement, which previously covered distribution in the United States, now includes over-the-counter wound care products for sale in both countries.
The expanded partnership aims to bring Sonoma's Microcyn® technology based stabilized hypochlorous acid (HOCl) products to Canadian patients, offering improved management of acute and chronic wounds. CEO Amy Trombly highlighted the distributor's expertise and network as key factors in reaching new patients and providing greater accessibility to consumers through over-the-counter products.
